Gentel® Signs Supply and Marketing License Agreement
News Aug 17, 2005
GenTel® BioSurfaces, Inc., and Kreatech Biotechnology BV have announced signing of an ULS™ Supply and Marketing License Agreement regarding the sales of ULS reagents for protein labeling and use on single capture antibody chips.
GenTel will market and sell the ULS labeling reagents under their brand name PANDEIA™ in diverse kit formats.
The kits are validated for use on GenTel's PATH™ protein microarray technology platform and will be launched during the upcoming Chips to Hits conference in Boston on September 12, 2005.
For one- or two-color fluorescent profiling of the relative abundance of proteins using single capture antibody arrays, each protein sample is labeled with either ULS-biotin or ULS-fluorescein, and probed against the antibody microarray.
The bound labeled proteins are detected using fluorescent Dy™ dyes from Dyomics GmbH using either a streptavidin-Dy™647 conjugate or an anti-fluorescein antibody-Dy™547 conjugate. The processed microarray is scanned on a standard two-color fluorescent scanner.
Kreatech, holder of a license from Dyomics GmbH (Jena, Germany), has sub-licensed the rights to market and sell the Dyomics' dye conjugates to GenTel.
GenTel's PATH protein microarray surface technology consists of an ultra-thin nitrocellulose film used for multiplex immunoassays.
GenTel's nitrocellulose coatings are designed to offer low auto-fluorescence and high signal-to noise.
"Our license of ULS and Dy dyes from Kreatech is another concrete example of GenTel's dedication to deliver new, cutting edge products to the antibody microarray market. Our immediate goal is to provide our customers with the best multiplex immunoassay products and accessories," said Robert Negm, Vice President, Business Development at GenTel.
"This agreement confirms the key benefits of our ULS technology for profiling of complex protein mixtures, like serum, on high content antibody arrays. The performance of ULS on GenTel's PATH array platform technology subscribes the wide platform compatibility of this unique protein labeling technology," said Roel Schaapveld, Director Business Development of Kreatech.
He adds, "The combination of ULS with GenTel's PATH Slides also opens the door to the significant 'homebrew' antibody array market."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.